Evotec SE (EVO)
USD 4.33
(-9.41%)
USD 4.33
(-9.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 115.28 Million EUR | 25.97% |
| 2022 | 91.51 Million EUR | 149.1% |
| 2021 | -186.4 Million EUR | -367.06% |
| 2020 | 69.8 Million EUR | -62.49% |
| 2019 | 186.06 Million EUR | 3339.28% |
| 2018 | 5.41 Million EUR | -95.6% |
| 2017 | 122.91 Million EUR | 323.02% |
| 2016 | -55.11 Million EUR | -155.7% |
| 2015 | -21.55 Million EUR | 20.64% |
| 2014 | -27.16 Million EUR | 4.37% |
| 2013 | -28.4 Million EUR | -31.11% |
| 2012 | -21.66 Million EUR | -1936.0% |
| 2011 | -1.06 Million EUR | 87.12% |
| 2010 | -8.26 Million EUR | 58.11% |
| 2009 | -19.72 Million EUR | 54.91% |
| 2008 | -43.73 Million EUR | -66.11% |
| 2007 | -26.33 Million EUR | 60.59% |
| 2006 | -66.81 Million EUR | -66.02% |
| 2005 | -40.24 Million EUR | -2598.26% |
| 2004 | -1.49 Million EUR | -469.06% |
| 2003 | 404.16 Thousand EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| 2001 | - EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 251.62 Million EUR | 26.29% |
| 2024 Q1 | 199.24 Million EUR | 72.82% |
| 2023 FY | 115.28 Million EUR | 25.97% |
| 2023 Q2 | 74.39 Million EUR | -89.65% |
| 2023 Q1 | 718.48 Million USD | 685.07% |
| 2023 Q3 | 89.37 Million EUR | 20.14% |
| 2023 Q4 | 115.28 Million EUR | 28.99% |
| 2022 Q4 | 91.51 Million USD | 224.78% |
| 2022 Q3 | 28.17 Million EUR | 113.18% |
| 2022 Q2 | -213.86 Million EUR | -50.69% |
| 2022 Q1 | -141.92 Million EUR | 23.87% |
| 2022 FY | 91.51 Million EUR | 149.1% |
| 2021 Q4 | -186.4 Million EUR | -211.48% |
| 2021 FY | -186.4 Million EUR | -367.06% |
| 2021 Q2 | 130.54 Million EUR | 13.05% |
| 2021 Q1 | 115.48 Million EUR | 65.44% |
| 2021 Q3 | 167.2 Million EUR | 28.08% |
| 2020 Q2 | 265.43 Million EUR | 52.55% |
| 2020 Q1 | 173.99 Million EUR | -6.49% |
| 2020 Q4 | 69.8 Million EUR | -70.77% |
| 2020 Q3 | 238.76 Million EUR | -10.05% |
| 2020 FY | 69.8 Million EUR | -62.49% |
| 2019 FY | 186.06 Million EUR | 3339.28% |
| 2019 Q4 | 186.06 Million EUR | -1.51% |
| 2019 Q3 | 188.91 Million EUR | 62.93% |
| 2019 Q1 | 115.57 Million EUR | 2036.4% |
| 2019 Q2 | 115.95 Million EUR | 0.32% |
| 2018 Q4 | 5.41 Million EUR | -62.81% |
| 2018 Q2 | 65.15 Million EUR | -48.06% |
| 2018 FY | 5.41 Million EUR | -95.6% |
| 2018 Q1 | 125.45 Million EUR | 2.07% |
| 2018 Q3 | 14.54 Million EUR | -77.68% |
| 2017 Q2 | -80.06 Million EUR | -15.55% |
| 2017 Q1 | -69.29 Million EUR | -25.72% |
| 2017 FY | 122.91 Million EUR | 323.02% |
| 2017 Q4 | 122.91 Million EUR | 6.95% |
| 2017 Q3 | 114.92 Million EUR | 243.53% |
| 2016 Q1 | -26.53 Million EUR | -23.09% |
| 2016 FY | -55.11 Million EUR | -155.7% |
| 2016 Q4 | -55.11 Million EUR | -15.63% |
| 2016 Q3 | -47.66 Million EUR | -20.01% |
| 2016 Q2 | -39.71 Million EUR | -49.7% |
| 2015 Q1 | -27.05 Million EUR | 0.4% |
| 2015 FY | -21.55 Million EUR | 20.64% |
| 2015 Q3 | -26.42 Million EUR | 27.59% |
| 2015 Q4 | -21.55 Million EUR | 18.44% |
| 2015 Q2 | -36.49 Million EUR | -34.91% |
| 2014 Q1 | -21.46 Million EUR | 24.43% |
| 2014 FY | -27.16 Million EUR | 4.37% |
| 2014 Q4 | -27.16 Million EUR | 19.51% |
| 2014 Q3 | -33.74 Million EUR | -56.08% |
| 2014 Q2 | -21.62 Million EUR | -0.72% |
| 2013 Q1 | -23.23 Million EUR | -7.24% |
| 2013 Q4 | -28.4 Million EUR | -16.41% |
| 2013 FY | -28.4 Million EUR | -31.11% |
| 2013 Q3 | -24.39 Million EUR | -26.08% |
| 2013 Q2 | -19.35 Million EUR | 16.7% |
| 2012 Q4 | -21.66 Million EUR | -22.27% |
| 2012 Q1 | 9.07 Million EUR | 952.54% |
| 2012 Q2 | 2.75 Million EUR | -69.64% |
| 2012 Q3 | -17.71 Million EUR | -743.32% |
| 2012 FY | -21.66 Million EUR | -1936.0% |
| 2011 Q3 | -14.22 Million EUR | -30.72% |
| 2011 Q4 | -1.06 Million EUR | 92.52% |
| 2011 Q1 | -26.52 Million EUR | -221.08% |
| 2011 Q2 | -10.88 Million EUR | 58.98% |
| 2011 FY | -1.06 Million EUR | 87.12% |
| 2010 Q4 | -8.26 Million EUR | -111.2% |
| 2010 FY | -8.26 Million EUR | 58.11% |
| 2010 Q3 | -3.91 Million EUR | 81.02% |
| 2010 Q2 | -20.61 Million EUR | -74.1% |
| 2010 Q1 | -11.84 Million EUR | 39.96% |
| 2009 Q4 | -19.72 Million EUR | 8.61% |
| 2009 Q1 | -31.71 Million EUR | 27.49% |
| 2009 Q2 | -29.45 Million EUR | 7.11% |
| 2009 Q3 | -21.58 Million EUR | 26.74% |
| 2009 FY | -19.72 Million EUR | 54.91% |
| 2008 Q2 | -29.9 Million EUR | -132.77% |
| 2008 Q4 | -43.73 Million EUR | -84.53% |
| 2008 Q3 | -23.7 Million EUR | 20.76% |
| 2008 FY | -43.73 Million EUR | -66.11% |
| 2008 Q1 | -12.84 Million USD | 50.24% |
| 2007 FY | -26.33 Million EUR | 60.59% |
| 2007 Q3 | -14.93 Million EUR | 0.0% |
| 2007 Q4 | -25.82 Million EUR | -72.93% |
| 2006 Q3 | -41.07 Million EUR | 13.45% |
| 2006 Q2 | -47.46 Million EUR | 16.56% |
| 2006 Q4 | -45.17 Million EUR | -9.96% |
| 2006 FY | -66.81 Million EUR | -66.02% |
| 2006 Q1 | -56.87 Million EUR | -1715.85% |
| 2005 FY | -40.24 Million EUR | -2598.26% |
| 2005 Q2 | -517.85 Thousand EUR | 71.2% |
| 2005 Q1 | -1.79 Million EUR | -20.56% |
| 2005 Q4 | -3.13 Million EUR | 0.0% |
| 2004 Q1 | -1.58 Million EUR | -492.41% |
| 2004 FY | -1.49 Million EUR | -469.06% |
| 2004 Q4 | -1.49 Million EUR | 0.0% |
| 2004 Q2 | -2.59 Million EUR | -63.71% |
| 2003 FY | 404.16 Thousand EUR | 0.0% |
| 2003 Q4 | 404.16 Thousand EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| 2001 FY | - EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -107788.9% |
| Harrow Health, Inc. | 116.41 Million USD | 0.969% |
| Dynavax Technologies Corporation | 106.63 Million USD | -8.116% |
| Biofrontera Inc. | 4.05 Million USD | -2742.431% |
| DURECT Corporation | -7.65 Million USD | 1606.258% |
| Cronos Group Inc. | -663.32 Million USD | 117.38% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 81.506% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 891.168% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 2323.068% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 1912.821% |
| Radius Health, Inc. | 359.28 Million USD | 67.911% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -58360.314% |
| ProPhase Labs, Inc. | 19.23 Million USD | -499.496% |
| Phibro Animal Health Corporation | 454.84 Million USD | 74.653% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 1322.612% |
| Procaps Group S.A. | 242.93 Million USD | 52.543% |
| Alvotech | 1.06 Billion USD | 89.168% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -3034.557% |
| Rockwell Medical, Inc. | 4.45 Million USD | -2487.276% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 837.395% |
| Alpha Teknova, Inc. | 1.97 Million USD | -5740.375% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 188.122% |
| SCYNEXIS, Inc. | -19.35 Million USD | 695.809% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 2463.933% |
| Theratechnologies Inc. | 24.87 Million USD | -363.548% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -22.378% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 4674.96% |
| Safety Shot Inc | -2.28 Million USD | 5146.851% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 443.869% |
| SIGA Technologies, Inc. | -148.68 Million USD | 177.541% |
| Tilray Brands, Inc. | 158.97 Million USD | 27.481% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 5.422% |
| Viatris Inc. | 17.13 Billion USD | 99.327% |
| PetIQ, Inc. | 351.93 Million USD | 67.241% |
| OptiNose, Inc. | 58.06 Million USD | -98.552% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 34.975% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 837.395% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -667.928% |
| Alimera Sciences, Inc. | 55.3 Million USD | -108.445% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 73.517% |
| Silver Spike Investment Corp. | -32.61 Million USD | 453.521% |
| Assertio Holdings, Inc. | -32.52 Million USD | 454.419% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 7844.159% |
| Cosmos Health Inc. | 8.59 Million USD | -1242.012% |
| Journey Medical Corporation | -9.7 Million USD | 1287.445% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 2378.266% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 2494.869% |
| Embecta Corp. | 1.31 Billion USD | 91.213% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 4073.526% |
| Procaps Group, S.A. | 242.93 Million USD | 52.543% |
| PainReform Ltd. | -7.95 Million USD | 1550.176% |
| Incannex Healthcare Limited | -5.48 Million USD | 2201.896% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1503.656% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -2633.91% |
| Shineco, Inc. | 29.29 Million USD | -293.608% |
| Talphera, Inc. | -5.72 Million USD | 2115.19% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 73.359% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -53.821% |
| Alvotech | 1.06 Billion USD | 89.168% |
| Hempacco Co., Inc. | 13.61 Million USD | -746.799% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -1513.562% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 219.211% |
| Bright Green Corporation | 1.84 Million USD | -6159.841% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 74.866% |
| Kamada Ltd. | -46.43 Million USD | 348.299% |
| Indivior PLC | -33.95 Million USD | 439.565% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -44144.245% |
| Flora Growth Corp. | -713 Thousand USD | 16269.565% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1503.656% |
| Evolus, Inc. | 63.7 Million USD | -80.965% |
| HUTCHMED (China) Limited | -197.45 Million USD | 158.387% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 75.937% |
| Akanda Corp. | 3.9 Million USD | -2852.407% |